Alexandra N Trelle, Christina B Young, Hillary Vossler, Javier Ramos Benitez, Karly A Cody, Justin H Mendiola, Michelle S Swarovski, Yann Le Guen, Igor Feinstein, Robert R Butler, Divya Channappa, America Romero, Jennifer Park, Marian Shahid-Besanti, Nicole K Corso, Kelly Chau, Amanda N Smith, Irina Skylar-Scott, Maya V Yutsis, Carolyn A Fredericks, Lu Tian, Kyan Younes, Geoffrey A Kerchner, Gayle K Deutsch, Guido A Davidzon, Sharon J Sha, Victor W Henderson, Frank M Longo, Michael D Greicius, Tony Wyss-Coray, Katrin I Andreasson, Kathleen L Poston, Anthony D Wagner, Elizabeth C Mormino, Edward N Wilson
INTRODUCTION: The availability of amyloid beta (Aβ) targeting therapies for Alzheimer''s disease (AD) is increasing the demand for scalable biomarkers that are sensitive to early cerebral Aβ accumulation.'
